LONDON (Alliance News) - Vectura Group PLC Friday said the lease covering its manufacturing facility in Lyon, France, has been transferred back to the company, which will now implement a number of initiatives to maximise the value from the asset.
Aenova France SAS held the lease of the manufacturing facility, which houses the oral product business in Saint-Quentin-Fallavier in Lyon, but this expired on Thursday and has now been returned to Vectura, it said.
"We are very pleased that the Lyon facility returns to the group at this exciting time. We have a strong high quality base with the return of the facility, and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology," said Vice President David Lescuyer.
The facility manufactures seven oral products for Vectura's partners.
Five products use the GeomatrixTM family of technologies: Diclofenac-ratiopharm-uno, Coruno, ZYFLO CR, Madopar DR/Prolopa and Sular whilst Lodotra/RAYOS uses the GeoclockTM chronotechnology. The facility also manufactures one other oral product, Triglide, based on the Vectura's solubilisation technology.
"A number of initiatives are underway to maximise the value of the facility now that it has returned to the group's control, leveraging proven capabilities in multilayer tableting, oral technology innovation and the high quality manufacturing capacity at the Lyon site," said Vectura.
By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
